MedTrace Logo

NG004 in Spinal Cord Injury Patients

NCT06817577 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-02-10

No results posted yet for this study

Summary

This is the FIH, multicenter, open-label, sequential, multiple ascending dose trial of NG004 in patients with acute incomplete cervical SCI. The trial will evaluate the safety, tolerability, and PK of 4 dose regimens of NG004, and will evaluate the maximum tolerated dose of NG004.

Conditions

  • Wounds and Injuries
  • Acute Spinal Cord Injury (SCI)
  • Spinal Cord Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Trauma, Nervous System
  • Spinal Cord Injuries (SCI)

Interventions

DRUG

NG004

repeated intrathecal injections of NG004

Sponsors & Collaborators

  • NovaGo Therapeutics AG

    lead INDUSTRY

Principal Investigators

  • Director of Clinical Research · NovaGo Therapeutics AG

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-18
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06817577 on ClinicalTrials.gov